Navigation Links
Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter
Date:9/3/2008

BRUSSELS, Belgium and GENEVA, Sept. 3 /PRNewswire/ -- Artelis SA and Selexis SA announced today a new milestone in CHO based monoclonal antibody production with the achievement of manufacturing yields of over 31 grams per liter. This record level was accomplished by applying two highly innovative technologies: (1) a high-performance stable Selexis CHO production cell line rapidly generated by industry leading scientists at Selexis SA using their proprietary Selexis Genetic Elements(TM) and (2) the application of iCELLis(TM) scalable, disposable, high-cell-density technology developed by the innovative scientists at Artelis.

The full program was concluded over about 4 months, starting with the development of a high-performance cell line development at Selexis, followed by cell transfer and manufacturing at Artelis. The culture media used throughout the study was industry standard cGMP grade and void of serum or any animal derived components.

Dr. Igor Fisch, Co-founder and CEO of Selexis commented on the achievements:

"The productivity and stability of the Selexis high-performance cell lines are a perfect fit for the iCELLis(TM) technology, which has the ability to reach incredibly high-cell-densities of up to 250 mio cells per ml". "The usefulness and potential applications of the combined approach could stretch across the biotech industry, beyond just large scale bioproduction".

Dr. Jose Castillo, Co-founder and President of Artelis commented on the achievements:

"These results show the power of the iCELLis(TM) technology. When combined with a high-performance cell line, like one from Selexis', we have the opportunity to reach ultra high productivity levels." "We firmly believe the iCELLis(TM) system will change the approach companies take for the small and large scale production of recombinant proteins."

Further details on this milestone achievement will be presented at the upcoming Bioprocess International Conferenc
'/>"/>

SOURCE Selexis
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
2. Previous Claims of siRNA Therapeutic Effects Called into Question by Report in Human Gene Therapy
3. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
4. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
5. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
6. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
7. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
8. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
9. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
10. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
11. New AVAC Report on Pre-Exposure Prophylaxis Calls for Immediate Planning to Anticipate Study Results of Potential New HIV Prevention Option

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)..., , MORRISVILLE, N.C., Dec. 1 /PRNewswi...der in the investigation of devices for minimally-...ounced the initiation of a feasibility clinical tr...f a combined surgical and catheter procedure, the ...atic paroxysmal atrial fibrillation (AF). This pr...
(Date:12/1/2009)..., , ALBUQUERQUE, N.M., Dec. 1 /PRNewswire/...ics laboratory that discovers, develops and market...ppointment of Scott Glenn as chairman of the compa...r. ,, Prior to joining Exagen, Glenn was managi...er of a number of successful biomedical companies ...
(Date:12/1/2009)..., , BRIDGEWATER, N.J., Dec. 1 /PRNewswir... Ortho Biotech Products, L.P., announced today tha...ess of issues affecting women and people of color ...aign including local educational events, media out... the company is sharing learnings from the GRACE s...
Breaking Medicine Technology:nContact Announces Initiation of Clinical Trials for the Treatment of Paroxysmal Atrial Fibrillation Utilizing New Convergent Ablation Procedure 2Scott Glenn Joins Exagen Diagnostics as Chairman and CEO 2Tibotec Therapeutics Launches GRACE Campaign for Women and People of Color Living With HIV/AIDS 2Tibotec Therapeutics Launches GRACE Campaign for Women and People of Color Living With HIV/AIDS 3Tibotec Therapeutics Launches GRACE Campaign for Women and People of Color Living With HIV/AIDS 4Tibotec Therapeutics Launches GRACE Campaign for Women and People of Color Living With HIV/AIDS 5Tibotec Therapeutics Launches GRACE Campaign for Women and People of Color Living With HIV/AIDS 6Tibotec Therapeutics Launches GRACE Campaign for Women and People of Color Living With HIV/AIDS 7WaferGen to Present at the Rodman and Renshaw Annual Global Investment Conference 13843 1WaferGen to Present at the Rodman and Renshaw Annual Global Investment Conference 13843 2WaferGen to Present at the Rodman and Renshaw Annual Global Investment Conference 13843 3European Urology September issue features Surgery in Motion article 56200 1NCI renews Fox Chase Penn Ovarian Cancer SPORE grant for a third 5 year term 56198 1NCI renews Fox Chase Penn Ovarian Cancer SPORE grant for a third 5 year term 56198 2NCI renews Fox Chase Penn Ovarian Cancer SPORE grant for a third 5 year term 56198 3NCI renews Fox Chase Penn Ovarian Cancer SPORE grant for a third 5 year term 56198 4
...h Health and,Roche Diagnostics Corporation have re...s in the growing field of molecular diagnostics. T...ertise in clinical testing,and care for patients w...che,s state-of-the-art technology to bring new dia...es are initially collaborating on the introduction...
...gene Target Discredited; Lower Dose, Array ...ffect, SAN DIMAS, Calif., Sept. 10 While the red... recently attracted scientific and,public attentio...e effects,of a calorie-restricted diet, the scienc...urn in recent months, according to Bill Sardi,spok...
Other Medicine Technology:National Jewish Health and Roche Diagnostics Corporation Reach Agreement to Pursue Environmental Molecular Diagnostics Opportunities 2Resveratrol Longevity Science Makes Dramatic U-Turn, But Resveratrol Supplements Remain Unchanged 2Resveratrol Longevity Science Makes Dramatic U-Turn, But Resveratrol Supplements Remain Unchanged 3Resveratrol Longevity Science Makes Dramatic U-Turn, But Resveratrol Supplements Remain Unchanged 4
(Date:12/1/2009)...NGELES, Dec. 1 Gooooooaaaaaal! ...kicks off its 2009/2010 growing season with a fres...nship with kids, soccer. Joy Fawcett - an award-w... the brand,s efforts to celebrate and mentor moms ...sponsorship expansion into Texas and a community-b...
(Date:12/1/2009)...ial, better access to treatment worldwide provide ...althDay News) -- While the war against HIV/AIDS is...ershed year in terms of advances in prevention and...s month a United Nations report found that the num...ned unchanged, at about 33 million, for the past t...
(Date:12/1/2009)... Pilots will enable local organizations to te...r for consumers who lack access , ...en Fund, a nonprofit venture firm addressing pover...t has selected four organizations in Kenya to cond... transportation and storage. , , ,The pilot progra...
(Date:12/1/2009)...Dec. 1 /PRNewswire/ - Sentinelle Medical Inc., a l...anced visualization software, extends its line of ...ical Society of North America (RSNA) annual meetin...Hall A). ,, With the unique Vanguard(R) patient...etry(TM), Sentinelle,s line of breast coils are re...
(Date:12/1/2009)... Amadeus will operate as a division of Xybion...lls, NJ (PRWEB) December 1, 2009 -- Xybion Corpora...uisition of all operating assets of Quebec City ba... of enterprise governance, risk, compliance and qu... a corporate performance management organization h...
Breaking Medicine News(10 mins):Health News:Olympic Gold Medalist, World Cup Champion and Soccer Hall of Famer Joy Fawcett Sports A New Uniform as an Official Cuties(R) California Mandarin and Clementine Spokes-Mom 2Health News:Olympic Gold Medalist, World Cup Champion and Soccer Hall of Famer Joy Fawcett Sports A New Uniform as an Official Cuties(R) California Mandarin and Clementine Spokes-Mom 3Health News:Olympic Gold Medalist, World Cup Champion and Soccer Hall of Famer Joy Fawcett Sports A New Uniform as an Official Cuties(R) California Mandarin and Clementine Spokes-Mom 4Health News:A Good Year in the Fight Against AIDS 2Health News:A Good Year in the Fight Against AIDS 3Health News:A Good Year in the Fight Against AIDS 4Health News:Acumen Fund Announces Ripple Effect Pilot Projects In Kenya To Identify Innovative Solutions To Water Challenges 2Health News:Acumen Fund Announces Ripple Effect Pilot Projects In Kenya To Identify Innovative Solutions To Water Challenges 3Health News:Acumen Fund Announces Ripple Effect Pilot Projects In Kenya To Identify Innovative Solutions To Water Challenges 4Health News:Sentinelle Medical Introduces New Suite of Breast MRI Coils for GE, Siemens and Toshiba Scanners 2Health News:Sentinelle Medical Introduces New Suite of Breast MRI Coils for GE, Siemens and Toshiba Scanners 3Health News:Xybion Acquires Amadeus, a Leader in Governance, Risk, Compliance and Quality Management (GRC) Solutions 2Health News:Xybion Acquires Amadeus, a Leader in Governance, Risk, Compliance and Quality Management (GRC) Solutions 3
...nce May; Miller to join WellPoint Sept. 15, INDIA...day,announced the appointments of Lori Beer as exe...r and Martin Miller as senior vice president, chie...nt and chief executive officer.,Beer has more than...
...ndon, New Delhi, Singapore, and Washington, DC (A...ity of nursing care through work environment chang... offset through improved nursing satisfaction and ...portance and Challenge of Paying for Quality Nursi...
...s patients can still take the cholesterol-lowering...s) -- U.S. drug regulators said Thursday that they...ng drug Vytorin might be linked to cancer. , The U...tin and Ezetimibe in Aortic Stenosis (SEAS) trial ...
...g. 22 Endocare, Inc.,(Nasdaq: ENDO ) announced t...s former CFO, John V. Cracchiolo, pursuant to whic...erminated in exchange for Endocare,s waiver,of cer...,s legal costs. As a result of this new agreement,...
... A ten-years acne sufferer shares his way ...atural way, saved from further scarring, and stopp...-the-counter products. , ...hout any harsh prescription drugs or the never-end...
... 22 Eli Lilly and Co (NYSE:,LLY) and Boehringer I...on,has approved the use of Cymbalta(R) (duloxetine...r (GAD). This approval -- the fourth for,duloxetin...oducts for Human Use (CHMP) on 26 June 2008., The...
Other Medicine News:Health News:WellPoint Announces Appointments of Lori Beer as Executive Vice President and Chief Information Officer; Martin Miller as Senior Vice President, Chief Accounting Officer and Controller 2Health News:The challenge of paying for quality nursing care 2Health News:FDA Investigates Possible Vytorin-Cancer Link 2Health News:FDA Investigates Possible Vytorin-Cancer Link 3Health News:Endocare and Former CFO Agree to Terminate Indemnification Agreement 2Health News:Chronic Acne Sufferer Finds a New Scientifically Proven Way to Permanently Clear Skin in 3 Days 2Health News:Cymbalta Receives European Approval for the Treatment of Generalised Anxiety Disorder 2Health News:Cymbalta Receives European Approval for the Treatment of Generalised Anxiety Disorder 3Health News:Cymbalta Receives European Approval for the Treatment of Generalised Anxiety Disorder 4Health News:Cymbalta Receives European Approval for the Treatment of Generalised Anxiety Disorder 5Health News:Cymbalta Receives European Approval for the Treatment of Generalised Anxiety Disorder 6
ADVIA IMS 800i Integrated Modular System
VS II Standalone
PSD 1
... in providing versatile liquid handling platforms ...livers even more flexibility and possibilities for...er with the new easy-to-use software, Freedom EVOw...te genomics, proteomics, and drug discovery applic...
Medicine Products: